Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Influenza
Findings from Baylor College of Medicine, College of Medicine advance knowledge in influenza
September 17th, 2008
According to a study from the United States, "Influenza viruses cause annual winter epidemics in temperate regions, with significant morbidity, mortality and economical impact. Fluarix(R) is a split, trivalent, inactivated vaccine, manufactured from highly purified, egg-grown influenza viruses by GlaxoSmithKline." "In 2005, Fluarix underwent accelerated approval for use in adults by the US FDA following a US-based, randomized, placebo-controlled trial that established its safety and immunogenicity in adults. The vaccine has been licensed in Europe since 1992 for all age groups. Multiple registration trials in all age groups in Europe have demonstrated that the vaccine...
Source: Vaccine Weekly (2008-09-17)
|
